Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Neural Stem Cell Transplantation in Traumatic Spinal Cord Injury
NCT02326662Phase 2Unknown
- Sponsor
- Federal Research Clinical Center of the FMBA
- Start
- Jul 2014
- Primary completion
- Oct 2018
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous neural stem cells in spinal cord injury (SCI) (6 arms), sponsored by Federal Research Clinical Center of the FMBA. Primary endpoint: Feasibility and safety of autologous Neural Stem Cell transplantation at 24 months. Status: unknown.
02
Drugs
autologous neural stem cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02326662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326662.